LRRK2 G2019S mutations are associated wi
β
Rachel Saunders-Pullman; Matthew J. Barrett; Kaili M. Stanley; Marta San Luciano
π
Article
π
2010
π
John Wiley and Sons
π
English
β 70 KB
## Abstract Leucine rich repeat kinase (__LRRK2__) G2019S mutations are presumed to cause PD through a toxic gain of function of the protein kinase. Small molecule kinase inhibitors have been developed for the treatment of certain cancers, and some antioncogenic agents such as sunitinib, may nonspe